Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice.
about
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideCell-cell fusion induced by measles virus amplifies the type I interferon response.The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) ProteinMembrane cofactor protein (MCP; CD46) expression in transgenic miceIn situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.Converting tumor-specific markers into reporters of oncolytic virus infection.In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein.Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.Stringent requirement for the C protein of wild-type measles virus for growth both in vitro and in macaques.Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice.Measles virus spreads in rat hippocampal neurons by cell-to-cell contact and in a polarized fashionImmature CD4+CD8+ thymocytes are preferentially infected by measles virus in human thymic organ culturesEarly events following experimental infection with Peste-Des-Petits ruminants virus suggest immune cell targetingMeasles virus V protein inhibits p53 family member p73Measles virus matrix protein specifies apical virus release and glycoprotein sorting in epithelial cells.Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approachAttenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.Oncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Engineered measles virus as a novel oncolytic therapy against prostate cancer.Measles virus for cancer therapy.Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.Use of attenuated paramyxoviruses for cancer therapy.Vaccine platform recombinant measles virus.Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Potential and clinical translation of oncolytic measles viruses.Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.Measles virus C protein interferes with Beta interferon transcription in the nucleus.Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage.Roles of macrophages in measles virus infection of genetically modified mice.Rational attenuation of a morbillivirus by modulating the activity of the RNA-dependent RNA polymerase.Strength of envelope protein interaction modulates cytopathicity of measles virus.A ferret model of canine distemper virus virulence and immunosuppression.Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infectionInterleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
P2860
Q24647228-6A3E8169-475C-4B0C-8B18-5EBA8685E79CQ27485028-F65E1CD6-510E-4C41-B7C1-E8696571307CQ28069519-3CC6141D-51B0-483B-A61A-E500C97E7391Q28367582-53A2DA61-56C5-4BFC-837F-CDE3C0145504Q30832171-7FA8B679-BEFC-465D-9F75-DC51B8C89FCDQ33605148-C142F6F4-880D-4A51-8C6A-02DCAA4D7E02Q33713865-26119013-EF37-4417-B8AB-A2D6DAD300DCQ33810639-25D110D1-8AA7-4F5A-A937-410C8E71384AQ33835693-4D48ADE6-3DA0-4EC1-B441-20D944CE66A3Q33843087-E9F8A5E0-50BE-44DB-8B9F-8DFDA53DD378Q34132250-A0AD2FB8-7082-4FFF-BA1E-524C4FF5B10EQ34365593-308C104F-623C-4A06-8A6C-EDBF1A6AAC63Q34430558-61E9A3F6-2044-476A-99DD-D6D11B4FD785Q34589606-7E795AFF-8883-418E-949E-9E2B5384DB20Q34648046-0D1BF8A9-B05F-4FFE-A3AF-808B39FC6D85Q35116287-80AA4EF6-4166-43E6-B7EF-0C1BB27A3E39Q36444231-F8C8F982-B3C9-44BA-823B-EDF13AB492E6Q36541009-E0751B7D-D55E-4C4C-A78E-3A619E392835Q36612202-9417F2DD-4235-4E05-815D-CFD4C15DE980Q36673332-74533EEB-B74F-4439-8FD3-7127DF1831CCQ37261017-C2A5C160-DCE5-46FA-8AAE-5BD86BA0B7A1Q37280354-BCB8CF0F-4510-4CC0-8816-499A14EEAD91Q37332702-5E1088D8-EF77-4572-99D4-E14EE22A5EFBQ37388577-51B9FBC3-F727-4DF7-A6BD-7632969C5A35Q37520259-544DC7D2-EA76-4813-A978-9FDC89F24E32Q37810599-327480C6-CF3B-45E3-B331-CD37768363C4Q38657271-8F5215AD-0ACD-44BC-9300-25457B93A5DBQ38754467-7FAEE432-4573-48C2-A5D1-3D23819A5829Q38764947-2D5CFE69-A0F5-4441-B241-10D4E237BC85Q38845078-8377C708-4F47-4B23-A0B5-629C7F28E91EQ39445395-080ED819-D9F7-42FC-867A-19D732BF6DD9Q39601579-2166061C-33A1-4FD8-BB5E-C03030FFC074Q39602305-798C0FA1-0483-4A58-94EB-84CDBC0E0369Q39612879-623D4428-E97A-42F3-B2D6-C5CC832133E7Q39683453-CBF0302E-7741-4F81-A661-89B01A19A2CEQ40173347-644B9237-3785-45E4-9CC2-FCC2A9B4DB5CQ41830437-D4A94197-801D-46BB-BC3F-79DC8F624210Q42133458-D2EE0062-48E6-4DBC-A982-E185A34CB1F4Q42937380-DE3C6A16-3F9A-4D60-BB37-86F36D9FE34F
P2860
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Lymphatic dissemination and co ...... in genetically modified mice.
@en
Lymphatic dissemination and co ...... in genetically modified mice.
@nl
type
label
Lymphatic dissemination and co ...... in genetically modified mice.
@en
Lymphatic dissemination and co ...... in genetically modified mice.
@nl
prefLabel
Lymphatic dissemination and co ...... in genetically modified mice.
@en
Lymphatic dissemination and co ...... in genetically modified mice.
@nl
P2093
P2860
P1433
P1476
Lymphatic dissemination and co ...... in genetically modified mice.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.3.1364-1372.2000
P407
P577
2000-02-01T00:00:00Z